Clinical Trials Logo

Keratoconjunctivitis Sicca clinical trials

View clinical trials related to Keratoconjunctivitis Sicca.

Filter by:

NCT ID: NCT02356341 Completed - Dry Eye Syndromes Clinical Trials

NovaTears® Eye Drops Observational Study NT-002

Start date: January 2015
Phase: N/A
Study type: Observational

This observational study is intended to collect outcome data from a cohort of 90 patients suffering from symptoms of dry eye disease due to meibomian gland dysfunction who are treated with the medical device NovaTears® eye drops for a duration of 6 to 8 weeks.

NCT ID: NCT02356328 Completed - Dry Eye Syndromes Clinical Trials

NovaTears® Eye Drops Observational Study NT-003

Start date: January 2015
Phase: N/A
Study type: Observational

This observational study is intended to collect outcome data from a cohort of 30 patients suffering from dry eye disease due to chronic ocular Graft-versus-Host Disease (GvHD) who are treated with the medical device NovaTears® eye drops for a duration of 11 to 13 weeks.

NCT ID: NCT02326090 Completed - Dry Eye Syndrome Clinical Trials

Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

Start date: December 2014
Phase: Phase 2
Study type: Interventional

The objective of the Phase 2 study is to compare the safety and efficacy of cis-UCA Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.

NCT ID: NCT02315079 Completed - Dry Eye Syndrome Clinical Trials

Point of Care Testing of Inflammatory Markers in Tears

Start date: January 2015
Phase:
Study type: Observational

To evaluate the use of a point of care device to measure markers of inflammation in various eye conditions. In particular, matrix metalloproteinase-9 (MMP-9) will be measured. MMP-9 is an enzyme that plays a role in inflammation. The value obtained with the point of care device will be correlated with values obtained using gel electrophoresis to measure MMP-9 from the same sample. These data will be compared to clinical exam findings and questionnaires to help the investigators better understand the role of this marker of inflammation in eye diseases and possibly improve diagnostic abilities.

NCT ID: NCT02313454 Completed - Dry Eye Syndromes Clinical Trials

Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye

Start date: November 17, 2014
Phase: N/A
Study type: Interventional

The purpose of this study was to evaluate the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally compared with the same device applied extranasally (control) in treating the symptoms of dry eye exacerbated by the Controlled Adverse Environment (CAE) Model.

NCT ID: NCT02284516 Completed - Dry Eye Disease Clinical Trials

A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)

OPUS-3
Start date: November 6, 2014
Phase: Phase 3
Study type: Interventional

Evaluate the efficacy and safety of Lifitegrast in subjects with dry eye disease and a recent history of artificial tear use.

NCT ID: NCT02280473 Completed - Dry Eye Syndromes Clinical Trials

A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease

Start date: November 13, 2014
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy o fRefresh Optive® Gel Drops in patients with dry eye disease.

NCT ID: NCT02260960 Completed - Dry Eye Disease Clinical Trials

The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease

Start date: March 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators hypothesize that oral omega-3-acid triglyceride form will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (TearOsmolarity, Schirmer-1 test values, corneal staining, and fluorescein tear break-up time) when compared to administration of placebo.

NCT ID: NCT02257957 Completed - Dry Eye Clinical Trials

Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye

Start date: November 30, 2014
Phase: Phase 3
Study type: Interventional

Dry eye is a chronic condition that decreases function and affect visual function with severe discapacity until now treatments are based in artificial eye drops. Platelet rich plasma has emerged as a strategy for cellular restoration, the purpose of this study is to evaluate their effects in lacrimal production and safety of this intervention in patients with severe dry eye.

NCT ID: NCT02254265 Completed - Dry Eye Disease Clinical Trials

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Start date: September 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo (vehicle) in patients with keratoconjunctivitis sicca (dry eye disease).